A Phase Ib Study Investigating the Combination of Everolimus With Trastuzumab and Vinorelbine in Patients With HER2-overexpressing Metastatic Breast Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To establish the feasible dose levels/regimens based on End-of-cycle-1 dose limiting toxicity (DLT)
after ever DLT within the first cycle, at least 21 days on treatment, every 2 months from first date of enrollment in a particular regimen
Yes
Novartis Pharmaceuticals
Study Director
Novartis Pharmeceuticals
United States: Food and Drug Administration
CRAD001J2102
NCT00426530
February 2007
Name | Location |
---|